Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013		Apr. 01, 2012
Segment Reporting Information [Line Items]
Gains (Losses) on Sales of Assets	$ 490		$ 0
Revenues	13,500		14,885
R&D Expenses	1,800	[1]	2,062	[1]
Earnings	3,921	[2]	2,435	[2]
Primary Care [Member]
Segment Reporting Information [Line Items]
Revenues	3,238	[3]	4,097	[3]
R&D Expenses	223	[3]	241	[3]
Earnings	2,014	[2],[3]	2,670	[2],[3]
Specialty Care And Oncology [Member]
Segment Reporting Information [Line Items]
Revenues	3,536		3,868
R&D Expenses	404		373
Earnings	2,314	[2]	2,596	[2]
Established Products and Emerging Markets [Member]
Segment Reporting Information [Line Items]
Revenues	4,772	[4]	5,100	[4]
R&D Expenses	64	[4]	73	[4]
Earnings	2,810	[2],[4]	3,177	[2],[4]
Reportable Segments [Member]
Segment Reporting Information [Line Items]
Revenues	11,546		13,065
R&D Expenses	691		687
Earnings	7,138	[2]	8,443	[2]
Other operating segments [Member]
Segment Reporting Information [Line Items]
Revenues	1,901	[5]	1,767	[5]
R&D Expenses	111	[5]	112	[5]
Earnings	448	[5]	353	[5]
Other business activities [Member]
Segment Reporting Information [Line Items]
Revenues	53	[6]	53	[6]
R&D Expenses	654	[6]	674	[6]
Earnings	(658)	[2],[6]	(681)	[2],[6]
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues	0	[7]	0	[7]
R&D Expenses	240	[7]	276	[7]
Earnings	(1,361)	[2],[7]	(1,705)	[2],[7]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues	0	[8]	0	[8]
R&D Expenses	(1)	[8]	(1)	[8]
Earnings	(1,232)	[2],[8]	(1,446)	[2],[8]
Acquisition-related Costs [Member]
Segment Reporting Information [Line Items]
Revenues	0	[9]	0	[9]
R&D Expenses	0	[8]	5	[8]
Earnings	(95)	[2],[9]	(183)	[2],[9]
Certain significant items [Member]
Segment Reporting Information [Line Items]
Revenues	0	[10]	0	[10]
R&D Expenses	93	[10]	302	[10]
Earnings	(128)	[10],[2]	(2,067)	[10],[2]
Other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues	0	[11]	0	[11]
R&D Expenses	12	[11]	7	[11]
Earnings	$ (191)	[11],[2]	$ (279)	[11],[2]

[1] Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

[2] Income from continuing operations before provision for taxes on income.

[3] Revenues and Earnings from the Primary Care segment decreased in the three months ended March 31, 2013 as compared to the three months ended April 1, 2012, and earnings as a percentage of revenues also declined, primarily due to the loss of exclusivity for Lipitor in developed Europe and Australia and the subsequent shift in the reporting of Lipitor in those markets to the Established Products business unit.

[4] Revenues and Earnings from the Established Products and Emerging Markets segment decreased in the three months ended March 31, 2013 as compared to the three months ended April 1, 2012, driven by, among other things, the expiration of the 180-day exclusivity period in the U.S. for atorvastatin and the loss of exclusivity in the U.S. for branded Lipitor, partially offset by the addition of products in certain markets that shifted to the Established Products unit from other business units beginning January 1, 2013. Earnings as a percentage of revenue decreased due to the change in the mix of products.

[5] Includes our Animal Health (Zoetis) operating segment and the Consumer Healthcare operating segment. The Animal Health earnings reflect the income before taxes of Zoetis on a management-reporting basis and generally include higher operating costs associated with being a standalone public company.

[6] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the R&D costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[7] Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities, and for Earnings includes, among other things, administration expenses, interest income/(expense), certain compensation and other costs not charged to our operating segments.

[8] Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

[9] Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information).

[10] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the first quarter of 2013, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $217 million, (ii) net credits for certain legal matters of $87 million, (iii) certain asset impairment charges of $396 million, (iv) gain associated with the transfer of certain product rights to our equity-method investment in China of $490 million, (v) costs associated with the separation of Zoetis of $76 million and (vi) other charges of $16 million. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment, Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions––Net.For Earnings in the first quarter of 2012, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $817 million, (ii) charges for certain legal matters of $775 million, (iii) certain asset impairment charges of $412 million, (iv) costs associated with the separation of Zoetis of $38 million and (v) other charges of $25 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions––Net.For R&D in all periods presented, certain significant items primarily reflect additional depreciation––asset restructuring and implementation costs.

[11] Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.